This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

William L. Whittington; Willard J. Castes, Jr, MD, MPH

JAMA. 1984;251(16):2116-2117.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Since biblical times, healers have sought an adequate therapy for genital herpes—albeit unsuccessfully.¹ During the last decade, however, research efforts have escalated, fueled in part by three interrelated phenomena: (1) the growing number of herpes sufferers demanding care from their physicians²; (2) increasing knowledge about the basic science of both the herpes simplex virus (HSV) and antiviral pharmacology³; and (3) the spiraling interest of government agencies and pharmaceutical companies as the public health implications and the potential market of those afflicted with herpes became clear. We now may be on the horizon of having a meaningful treatment for genital herpes—yet, at the same time, we must proceed cautiously.

The antiviral agent acyclovir offers a genuine ray of hope to patients with herpes—both as an effective treatment and as potential prophylaxis. The report by Reichman and colleagues⁴ in this issue of THE JOURNAL . . . [Full Text PDF of this Article]

Author Affiliations
Centers for Disease Control Atlanta

Footnotes
Address editorial communications to the Editor, 535 N Dearborn St, Chicago, IL 60610.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?